[EN] SUBSTITUTED INDAZOLE COMPOUNDS AS RORGAMMAT INHIBITORS AND USES THEREOF<br/>[FR] COMPOSÉS INDAZOLE SUBSTITUÉS UTILISÉS EN TANT QU'INHIBITEURS DE RORGAMMAT ET UTILISATIONS ASSOCIÉES
申请人:MERCK SHARP & DOHME
公开号:WO2017075182A1
公开(公告)日:2017-05-04
The present invention relates to compounds according to Formula (I) and pharmaceutically acceptable salts thereof. Such compounds can be used in the treatment of RORgammaT-mediated diseases or conditions.
[EN] 6-(5-HYDROXY-1H-PYRAZOL-1-YL)NICOTINAMIDE DERIVATIVES AND THEIR USE AS PHD INHIBITORS<br/>[FR] INHIBITEURS 6-(5-HYDROXY-1H-PYRAZOL-1-YL)NICOTINAMIDE DE PHD
申请人:TAKEDA PHARMACEUTICAL
公开号:WO2014160810A1
公开(公告)日:2014-10-02
The present invention provides compounds of formula (I) which are useful as inhibitors of PHD, pharmaceutical compositions thereof, methods for treatment of conditions associated with HIF, processes for making the compounds and intermediates thereof.
[EN] COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY<br/>[FR] COMPOSÉS POUR LE TRAITEMENT D'UNE AMYOTROPHIE SPINALE
申请人:HOFFMANN LA ROCHE
公开号:WO2016184832A1
公开(公告)日:2016-11-24
The present invention provides compounds of formula (I) wherein A, X, Y, R1 and R2 are as described herein, as well as pharmaceutically acceptable salts thereof. Further the present invention is concerned with the manufacture of the compounds of formula (I), pharmaceutical compositions comprising them and their use as medicaments.
[EN] 1H-BENZO[D]IMIDAZOLE DERIVATIVES AS TLR9 INHIBITORS FOR THE TREATMENT OF FIBROSIS<br/>[FR] DÉRIVÉS DE 1H-BENZO[D]IMIDAZOLE UTILISÉS EN TANT QU'INHIBITEURS DE TLR9 POUR LE TRAITEMENT DE LA FIBROSE
申请人:BRISTOL MYERS SQUIBB CO
公开号:WO2022040260A1
公开(公告)日:2022-02-24
The present invention relates to lH-benzo[d]imidazole derivatives of formula (I) or a salt thereof. The present compounds are inhibitors of TLR9 and useful in treating preventing, or slowing fibrotic diseases, such as e.g. liver fibrosis, renal fibrosis, biliary fibrosis or pancreatic fibrosis, nonalcoholic steatohepatitis (NASH), non-alcoholic fatty liver disease (NAFLD), chronic kidney disease, diabetic kidney disease, primary sclerosing cholangitis (PSC) or primary biliary cirrhosis (PBC), or idiopathic pulmonary fibrosis (IPF).
[EN] PYRIDAZINYL AMINO DERIVATIVES AS ALK5 INHIBITORS<br/>[FR] DÉRIVÉS D'AMINO PYRIDAZINYLE UTILISÉS EN TANT QU'INHIBITEURS D'ALK5
申请人:CHIESI FARM SPA
公开号:WO2022013307A1
公开(公告)日:2022-01-20
The present invention relates to a compound of general formula (I) inhibiting the transforming growth factor-β (TGF-β) type I receptor (ALK5), methods of preparing such compounds, pharmaceutical compositions containing them and therapeutic use thereof. The compounds of the invention may be useful in the treatment of diseases or conditions associated with a dysregulation of ALK5 signaling pathway in a mammal.